Continuous intestinal exposure to glucose influences the secretion and action of incretins, including gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), which contribute to a reduction in glycaemia, often observed in patients, regardless of the history of DM, undergoing EN [8,11,12]. This evidence concerns the gene GIP and diabetes mellitus.